About: Abstract The coronavirus-19 (COVID-19) pandemic poses a significant risk to patients undergoing hematopoietic stem cell transplant or cellular therapy. The American Society for Transplantation and Cellular Therapy Pharmacy Special Interest Group Steering Committee aims to provide pharmacy practice management recommendations for how to transition clinical hematopoietic stem cell transplant (HCT) or cellular therapy pharmacy services utilizing telemedicine capabilities in the inpatient and outpatient setting to maintain an equivalent level of clinical practice but minimizing viral spread in a high risk, immunocompromised population. Additionally, the Steering Committee offers clinical management recommendations for COVID-19 in HCT and cellular therapy patients based on the rapidly developing literature. As the therapeutic and supportive care interventions for COVID-19 increase, collaboration with clinical pharmacy providers is critical to ensure safe administration in HCT patients. Attention to drug-drug interactions (DDI) and toxicity, particularly QTc prolongation, warrants close cardiac monitoring and potential cessation of concomitant QTc prolonging agents. Expanded indications for hydroxychloroquine and tocilizumab have already shown potential stress to usual supply chain. Detailed prescribing algorithms, decision pathways and specific patient population stock may be necessary. The COVID-19 pandemic has challenged every member of the healthcare team and we must continue to remain vigilant in providing pharmacy clinical services to one of the most high-risk patient populations and remain committed to providing compassionate and safe care for patients receiving HCT and cellular therapies.   Goto Sponge  NotDistinct  Permalink

An Entity of Type : fabio:Abstract, within Data Space : covidontheweb.inria.fr associated with source document(s)

AttributesValues
type
value
  • Abstract The coronavirus-19 (COVID-19) pandemic poses a significant risk to patients undergoing hematopoietic stem cell transplant or cellular therapy. The American Society for Transplantation and Cellular Therapy Pharmacy Special Interest Group Steering Committee aims to provide pharmacy practice management recommendations for how to transition clinical hematopoietic stem cell transplant (HCT) or cellular therapy pharmacy services utilizing telemedicine capabilities in the inpatient and outpatient setting to maintain an equivalent level of clinical practice but minimizing viral spread in a high risk, immunocompromised population. Additionally, the Steering Committee offers clinical management recommendations for COVID-19 in HCT and cellular therapy patients based on the rapidly developing literature. As the therapeutic and supportive care interventions for COVID-19 increase, collaboration with clinical pharmacy providers is critical to ensure safe administration in HCT patients. Attention to drug-drug interactions (DDI) and toxicity, particularly QTc prolongation, warrants close cardiac monitoring and potential cessation of concomitant QTc prolonging agents. Expanded indications for hydroxychloroquine and tocilizumab have already shown potential stress to usual supply chain. Detailed prescribing algorithms, decision pathways and specific patient population stock may be necessary. The COVID-19 pandemic has challenged every member of the healthcare team and we must continue to remain vigilant in providing pharmacy clinical services to one of the most high-risk patient populations and remain committed to providing compassionate and safe care for patients receiving HCT and cellular therapies.
Subject
  • Stem cells
  • COVID-19
  • Pharmacy
  • Channelopathies
part of
is abstract of
is hasSource of
Faceted Search & Find service v1.13.91 as of Mar 24 2020


Alternative Linked Data Documents: Sponger | ODE     Content Formats:       RDF       ODATA       Microdata      About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data]
OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software